59 related articles for article (PubMed ID: 360234)
1. Baclofen in the treatment of schizophrenia: a pilot study.
Schöpf J; Hucker H
Pharmakopsychiatr Neuropsychopharmakol; 1977 Mar; 10(2):89-91. PubMed ID: 360234
[TBL] [Abstract][Full Text] [Related]
2. Baclofen (para-chlorphenyl-GABA) in schizophrenia.
Beckmann H; Frische M; Rüther E; Zimmer R
Pharmakopsychiatr Neuropsychopharmakol; 1977 Jan; 10(1):26-31. PubMed ID: 329292
[TBL] [Abstract][Full Text] [Related]
3. Baclofen in chronic schizophrenia.
Bigelow LB
Psychopharmacol Bull; 1977 Jan; 13(1):4-5. PubMed ID: 319473
[No Abstract] [Full Text] [Related]
4. [Neuroleptic effect of baclofen in chronic schizophrenia (author's transl)].
Kuhn R
Arzneimittelforschung; 1976; 26(6):1187. PubMed ID: 989412
[TBL] [Abstract][Full Text] [Related]
5. Baclofen in the treatment of tardive dyskinesia and schizophrenia.
Simpson GM; Lee JH; Shrivastava RK; Branchey MH
Psychopharmacol Bull; 1978 Apr; 14(2):16-8. PubMed ID: 349598
[No Abstract] [Full Text] [Related]
6. Baclofen treatment for chronic posttraumatic stress disorder.
Drake RG; Davis LL; Cates ME; Jewell ME; Ambrose SM; Lowe JS
Ann Pharmacother; 2003 Sep; 37(9):1177-81. PubMed ID: 12921495
[TBL] [Abstract][Full Text] [Related]
7. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
Bralet MC; Yon V; Loas G; Noisette C
Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
[TBL] [Abstract][Full Text] [Related]
8. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
9. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
[TBL] [Abstract][Full Text] [Related]
10. Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results.
Schied HW; Rein W; Straube E; Jung H; Breyer-Pfaff U
Pharmacopsychiatria; 1983 Sep; 16(5):152-9. PubMed ID: 6140694
[TBL] [Abstract][Full Text] [Related]
11. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
[TBL] [Abstract][Full Text] [Related]
12. Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
Pacquay M; Brasseur F
Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):46-9. PubMed ID: 798190
[TBL] [Abstract][Full Text] [Related]
13. Bromocriptine in augmentation of antipsychotic response in chronic schizophrenia: a negative pilot report.
Wells BG; Chu CC; Abi-Darghum A; Saini TS
Pharmacopsychiatry; 1991 Jul; 24(4):118-20. PubMed ID: 1684441
[TBL] [Abstract][Full Text] [Related]
14. An open study of mesoridazine (Serentil) in chronic schizophrenics.
Aguilar SJ
Dis Nerv Syst; 1975 Sep; 36(9):484-9. PubMed ID: 1175465
[TBL] [Abstract][Full Text] [Related]
15. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical effects of nicergoline in chronic schizophrenic patients.
Albus M; Botschev C; Müller-Spahn F; Naber D; Münch U; Ackenheil M
Pharmacopsychiatry; 1986 May; 19(3):101-5. PubMed ID: 3725889
[TBL] [Abstract][Full Text] [Related]
17. Lioresal (baclofen) treatment of spasticity in multiple sclerosis.
Basmajian JV
Am J Phys Med; 1975 Aug; 54(4):175-7. PubMed ID: 1098477
[No Abstract] [Full Text] [Related]
18. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
[TBL] [Abstract][Full Text] [Related]
19. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia.
Yamagami S; Soejima K
Drugs Exp Clin Res; 1989; 15(4):171-6. PubMed ID: 2570687
[TBL] [Abstract][Full Text] [Related]
20. Loxapine succinate: a controlled double-blind study in chronic schizophrenia.
Schiele BC
Dis Nerv Syst; 1975 Jul; 36(7):361-4. PubMed ID: 1097221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
